Economic Burden and Disparities in Healthcare Resource Use Among Adult Patients with Cardiac Arrhythmia

2013 ◽  
Vol 12 (1) ◽  
pp. 59-71 ◽  
Author(s):  
Derek H. Tang ◽  
Adrienne M. Gilligan ◽  
Klaus Romero
Keyword(s):  
Cardiac Arrhythmia ◽  
Resource Use ◽  
Economic Burden ◽  
Healthcare Resource ◽  
Adult Patients ◽  
Healthcare Resource Use

scholarly journals Economic analysis of the prevalence and clinical and economic burden of medication error in England

2020 ◽  
pp. bmjqs-2019-010206 ◽  
Author(s):  
Rachel Ann Elliott ◽  
Elizabeth Camacho ◽  
Dina Jankovic ◽  
Mark J Sculpher ◽  
Rita Faria
Keyword(s):  
Primary Care ◽  
Medication Errors ◽  
Resource Use ◽  
Economic Burden ◽  
Secondary Care ◽  
Healthcare Resource ◽  
Annual Number ◽  
Healthcare Resource Use ◽  
Clinically Significant ◽  
Potentially Clinically Significant

ObjectivesTo provide national estimates of the number and clinical and economic burden of medication errors in the National Health Service (NHS) in England.MethodsWe used UK-based prevalence of medication errors (in prescribing, dispensing, administration and monitoring) in primary care, secondary care and care home settings, and associated healthcare resource use, to estimate annual number and burden of errors to the NHS. Burden (healthcare resource use and deaths) was estimated from harm associated with avoidable adverse drug events (ADEs).ResultsWe estimated that 237 million medication errors occur at some point in the medication process in England annually, 38.4% occurring in primary care; 72% have little/no potential for harm and 66 million are potentially clinically significant. Prescribing in primary care accounts for 34% of all potentially clinically significant errors. Definitely avoidable ADEs are estimated to cost the NHS £98 462 582 per year, consuming 181 626 bed-days, and causing/contributing to 1708 deaths. This comprises primary care ADEs leading to hospital admission (£83.7 million; causing 627 deaths), and secondary care ADEs leading to longer hospital stay (£14.8 million; causing or contributing to 1081 deaths).ConclusionsUbiquitous medicines use in health care leads unsurprisingly to high numbers of medication errors, although most are not clinically important. There is significant uncertainty around estimates due to the assumption that avoidable ADEs correspond to medication errors, data quality, and lack of data around longer-term impacts of errors. Data linkage between errors and patient outcomes is essential to progress understanding in this area.

scholarly journals The Incidence and Economic Burden of Extrapyramidal Symptoms in Patients with Schizophrenia Treated with Atypical Antipsychotics

CNS Spectrums ◽  
2021 ◽  
Vol 26 (2) ◽  
pp. 168-169
Author(s):  
Aditi Kadakia ◽  
Brenna L. Brady ◽  
Huan Huang ◽  
Carole Dembek ◽  
G. Rhys Williams ◽  
...  
Keyword(s):  
Resource Use ◽  
Economic Burden ◽  
Atypical Antipsychotics ◽  
Healthcare Resource ◽  
Treatment Options ◽  
Healthcare Resource Utilization ◽  
Extrapyramidal Symptoms ◽  
Emergency Room Visits ◽  
Healthcare Resource Use ◽  
Icd 10

AbstractObjectiveExtrapyramidal symptoms (EPS), including movement disorders, tremors, and muscle contractions are common side effects of atypical antipsychotic (AAP) drugs in patients with schizophrenia. This study examined the incidence and burden of EPS in patients with schizophrenia initiating AAPs.MethodsPatients with schizophrenia initiating AAPs with no prior EPS were identified in the MarketScan Multi-state Medicaid database from 1/1/2012-12/31/2018. Incidence of EPS (identified via ICD-9/ICD-10 diagnoses and medications) was assessed during the 12-months following AAP initiation. Cohorts with and without EPS were defined. Demographics, clinical characteristics, and healthcare resource use and costs over 12 months following the first EPS claim (EPS) or randomly assigned index date (Non-EPS) were assessed.ResultsA total of 11,642 patients with schizophrenia were identified; 21.2% developed EPS in the 12-months following AAP initiation. EPS and Non-EPS cohorts included 2,295 (mean age 38, 61% male, CCI 0.6) and 5,607 (mean age 39, 57% male, CCI 0.7) patients, respectively. Over the 12-month post-index period, EPS cohort had significantly higher rates of all-cause (30.2% vs. 24.6%, p<0.001) and schizophrenia-related hospitalizations (22.5% vs. 12.9%, p<0.001) and schizophrenia-related emergency room visits (25.5% vs. 16.7%, p<0.001) compared to Non-EPS cohort. All-cause ($25,911 vs. $21,550, p<0.001) and schizophrenia-related healthcare costs ($12,134 vs. $6,230, p<0.001) were significantly higher in EPS vs. Non-EPS cohort.ConclusionsIn the 12 months following AAP initiation, over 20% of schizophrenia patients developed EPS, which was associated with increased healthcare resource utilization and costs. Treatment options that minimize EPS may reduce the economic burden of schizophrenia.FundingSunovion Pharmaceuticals Inc.

scholarly journals Predictors of poor health and functional recovery following road trauma: protocol of a British Columbian inception cohort study

BMJ Open ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. e049623
Author(s):  
Leona K Shum ◽  
Herbert Chan ◽  
Shannon Erdelyi ◽  
Lulu X Pei ◽  
Jeffrey R Brubacher
Keyword(s):  
Resource Use ◽  
Healthcare Resource ◽  
Healthcare Providers ◽  
Healthcare Resource Use ◽  
Physical And Mental Health ◽  
Inception Cohort ◽  
Policy Makers ◽  
Productivity Costs ◽  
Poor Outcome ◽  
Lost Productivity

IntroductionRoad trauma (RT) is a major public health problem affecting physical and mental health, and may result in prolonged absenteeism from work or study. It is important for healthcare providers to know which RT survivors are at risk of a poor outcome, and policy-makers should know the associated costs. Unfortunately, outcome after RT is poorly understood, especially for RT survivors who are treated and released from an emergency department (ED) without the need for hospital admission. Currently, there is almost no research on risk factors for a poor outcome among RT survivors. This study will use current Canadian data to address these knowledge gaps.Methods and analysisWe will follow an inception cohort of 1500 RT survivors (16 years and older) who visited a participating ED within 24 hours of the accident. Baseline interviews determine pre-existing health and functional status, and other potential risk factors for a poor outcome. Follow-up interviews at 2, 4, 6, and 12 months (key stages of recovery) use standardised health-related quality of life tools to determine physical and mental health outcome, functional recovery, and healthcare resource use and lost productivity costs.Ethics and disseminationThe Road Trauma Outcome Study is approved by our institutional Research Ethics Board. This study aims to provide healthcare providers with knowledge on how quickly RT survivors recover from their injuries and who may be more likely to have a poor outcome. We anticipate that this information will be used to improve management of all road users following RT. Healthcare resource use and lost productivity costs will be collected to provide a better cost estimate of the effects of RT. This information can be used by policy-makers to make informed decisions on RT prevention programmes.

Sign in / Sign up

Export Citation Format

Share Document